logo

For the Inventor, By the Inventor

Foster City, CA, United States of America

Gilead Biologics, Inc.

USPTO Granted Patents = 16

% Expired Patents = 18.8



Forward Citations = 121

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal Victoria Smith (13 out of 312 patents)

silverMedal Scott Alan McCauley (13 out of 19 patents)

bronzeMedal Alison Kay Holzer (7 out of 7 patents)

4.  Hector Rodriguez (6 out of 10 patents)

5.  Carlos Aurelio Garcia (6 out of 6 patents)

6.  Scott Ogg (5 out of 6 patents)

7.  Peter Van Vlasselaer (5 out of 19 patents)

8.  Vivian E Barry (5 out of 5 patents)

9.  Miho Oyasu (5 out of 5 patents)

10.  Donna Hiroko Tokuoka Biermann (5 out of 5 patents)

11.  Derek Marshall (5 out of 8 patents)

12.  Maria Vaysberg (3 out of 4 patents)

13.  Michael J Hawkins (1 out of 3 patents)

14.  Joanne I Adamkewicz (1 out of 1 patent)

15.  Zung Thai (1 out of 1 patent)


16 patents:

1. 10800857 - Antibodies to matrix metalloproteinase 9 (2020-10-13),
2. 10494443 - LOX and LOXL2 inhibitors and uses thereof (2019-12-03),
3. 9732156 - Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9 (2017-08-15),
4. 9550836 - Method of detecting human matrix metalloproteinase 9 using antibodies (2017-01-24),
5. 9289447 - Chemotherapeutic methods and compositions (2016-03-22),
6. 9260532 - Antibodies to matrix metalloproteinase 9 (2016-02-16),
7. 9176139 - LOX and LOXL2 inhibitors and uses thereof (2015-11-03),
8. 9107935 - Chemotherapeutic methods and compositions (2015-08-18),
9. 8927700 - Catalytic domains from lysyl oxidase and LOXL2 (2015-01-06),
10. 8680246 - Antibodies that bind to lysyl oxidase-like 2 (LOXL2) (2014-03-25),
11. 8679485 - Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis (2014-03-25),
12. 8658167 - Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis (2014-02-25),
13. 8512990 - Catalytic domains from lysyl oxidase and LOXL2 (2013-08-20),
14. 8501916 - Antibodies to matrix metalloproteinase 9 (2013-08-06),
15. 8461303 - LOX and LOXL2 inhibitors and uses thereof (2013-06-11),
Company Overview
Gilead Biologics, Inc., based in Foster City, California, specializes in the development and manufacturing of innovative biologic therapies. The company focuses on advancing treatments for various diseases, particularly in the fields of oncology, infectious diseases, and inflammatory conditions. Gilead is committed to leveraging cutting-edge research and technology to enhance patient outcomes and address unmet medical needs, positioning itself as a leader in the biopharmaceutical industry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

16 Patents

#28 in Foster City, CA

#4,777 in California

#19,935 in US

#37,868 in the World

Foster City, CA (US)
Foster City, CA, United States of America

Gilead Biologics, Inc.

Forward Citations = 121

13 inventors:

goldMedal Victoria Smith (13 out of 312 patents)

silverMedal Scott Alan McCauley (13 out of 19 patents)

bronzeMedal Alison Kay Holzer (7 out of 7 patents)

4.  Hector Rodriguez (6 out of 10 patents)

5.  Carlos Aurelio Garcia (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gilead Biologics, Inc.. Retrieved from https://idiyas.com/company/gilead-biologics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…